acquired
Stage
2
Investors
About
Aerovate Therapeutics is a clinical-stage biopharmaceutical company focused on developing inhaled therapies for patients with debilitating pulmonary diseases. Its lead product candidate is an inhaled formulation of an established anti-fibrotic agent for the treatment of idiopathic pulmonary fibrosis.
Explore Aerovate Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.